ALDX (Aldeyra Therapeutics) 3-Year Dividend Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALDX Aldeyra Therapeutics Inc ALDX
30 GF Score
Price $1.49
! 1 Warning Sign
View Full Analysis

What is Aldeyra Therapeutics 3-Year Dividend Growth Rate?

Aldeyra Therapeutics ALDX -0.67% 30 3-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates ALDX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 95 Biotechnology companies, Aldeyra Therapeutics ranks worse than 1052630.53% on this metric.

Aldeyra Therapeutics's Dividends per Share for the three months ended in Jun. 2026 was $0.00.

The historical rank and industry rank for Aldeyra Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

ALDX's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Aldeyra Therapeutics's Dividend Payout Ratio for the three months ended in Jun. 2026 was 0.00. As of today, Aldeyra Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Aldeyra Therapeutics  (NAS:ALDX) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Aldeyra Therapeutics's Dividend Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2026 )/ EPS without NRI (Q: Jun. 2026 )
=0/ -0.09
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aldeyra Therapeutics 3-Year Dividend Growth Rate Related Terms>


ALDX vs RLYB, DWTX, ICCC: 3-Year Dividend Growth Rate Comparison

For the Biotechnology subindustry, Aldeyra Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics 3-Year Dividend Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's 3-Year Dividend Growth Rate falls into.


ALDX
30GF Score
Aldeyra Therapeutics Inc ALDX
3-Year Dividend Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aldeyra Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Dividend Growth Rate of 0.00% mean?
Aldeyra Therapeutics (ALDX) has a 3-Year Dividend Growth Rate of 0.00% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Aldeyra Therapeutics and its competitors. According to the industry distribution chart, Aldeyra Therapeutics ranks #999999 out of 95 companies in the Biotechnology industry.
Is Aldeyra Therapeutics' 3-Year Dividend Growth Rate too high?
Aldeyra Therapeutics' current 3-Year Dividend Growth Rate is 0.00%. Based on the distribution chart, Aldeyra Therapeutics ranks #999999 out of 95 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aldeyra Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' 3-Year Dividend Growth Rate compare to RLYB and DWTX?
According to the Biotechnology industry distribution chart, Aldeyra Therapeutics ranks #999999 out of 95 companies for 3-Year Dividend Growth Rate. This places Aldeyra Therapeutics in the lower half of its industry. The industry median 3-Year Dividend Growth Rate is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Biotechnology company?
The median 3-Year Dividend Growth Rate among Biotechnology companies is 5.20, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Aldeyra Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year Dividend Growth Rate is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aldeyra Therapeutics's current 3-Year Dividend Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current 3-Year Dividend Growth Rate of 0.00%. The current 3-Year Dividend Growth Rate is 0.00%. Aldeyra Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current 3-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aldeyra Therapeutics Business Description

Other Exchanges 137:Germany
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
30GF Score

Get the complete analysis for ALDX

3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.49
Price